PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitlmayr, S.* ; Zierler, S.* ; Staab-Weijnitz, C.A. ; Dietrich, A.* ; Geiger, F.* ; Horgen, F.D.* ; Gudermann, T.* ; Breit, A.*

TRPM7 restrains plasmin activity and promotes transforming growth factor-β1 signaling in primary human lung fibroblasts.

Arch. Toxicol. 96, 2767-2783 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Sustained exposure of the lung to various environmental or occupational toxins may eventually lead to pulmonary fibrosis, a devastating disease with no cure. Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix (ECM) proteins such as fibronectin and collagens. The peptidase plasmin degrades the ECM, but protein levels of the plasmin activator inhibitor-1 (PAI-1) are increased in fibrotic lung tissue, thereby dampening plasmin activity. Transforming growth factor-β1 (TGF-β1)-induced activation of SMAD transcription factors promotes ECM deposition by enhancing collagen, fibronectin and PAI-1 levels in pulmonary fibroblasts. Hence, counteracting TGF-β1-induced signaling is a promising approach for the therapy of pulmonary fibrosis. Transient receptor potential cation channel subfamily M Member 7 (TRPM7) supports TGF-β1-promoted SMAD signaling in T-lymphocytes and the progression of fibrosis in kidney and heart. Thus, we investigated possible effects of TRPM7 on plasmin activity, ECM levels and TGF-β1 signaling in primary human pulmonary fibroblasts (pHPF). We found that two structurally unrelated TRPM7 blockers enhanced plasmin activity and reduced fibronectin or PAI-1 protein levels in pHPF under basal conditions. Further, TRPM7 blockade strongly inhibited fibronectin and collagen deposition induced by sustained TGF-β1 stimulation. In line with these data, inhibition of TRPM7 activity diminished TGF-β1-triggered phosphorylation of SMAD-2, SMAD-3/4-dependent reporter activation and PAI-1 mRNA levels. Overall, we uncover TRPM7 as a novel supporter of TGF-β1 signaling in pHPF and propose TRPM7 blockers as new candidates to control excessive ECM levels under pathophysiological conditions conducive to pulmonary fibrosis.
Impact Factor
Scopus SNIP
Altmetric
6.168
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Plasmin ; Primary Human Lung Fibroblasts ; Pulmonary Fibrosis ; Tgf-β1 ; Trpm7
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0340-5761
e-ISSN 1432-0738
Quellenangaben Band: 96, Heft: 10, Seiten: 2767-2783 Artikelnummer: , Supplement: ,
Verlag Springer
Begutachtungsstatus Peer reviewed
POF Topic(s) 80000 - German Center for Lung Research
30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501800-817
G-501600-001
Förderungen NIGMS NIH HHS
Deutsche Forschungsgemeinschaft
Scopus ID 85134488208
PubMed ID 35864199
Erfassungsdatum 2022-11-03